Providing a steady flow of breaking news, analysis, news briefs, document texts and more, all designed to ensure you have the best, most complete information available anywhere about what’s happening in drug pricing.

The Medicaid and CHIP Payment and Access Commission (MACPAC) on Friday (Jan. 27) voted to recommend Congress grant states the ability to impose Medicaid coverage limitations on drugs approved by FDA that lack full evidence of efficacy and for which CMS restricts Medicare coverage as more evidence is gathered on whether the drugs work.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.